113 results about "Fat mass" patented technology

Disclosed herein are “ketone body-HMB” or “KB-HMB” compositions including a combination of: (1) hydroxymethyl butyrate; (2) a ketone body component such as beta-hydroxybutyrate (BHB) and / or acetoacetate; and (3) optionally a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such compositions for producing desired physiological effects, such as fat loss, in a mammal. The compositions beneficially enhance fat loss through ketosis while also reducing or eliminating muscle wasting and / or promoting muscle formation.

The invention belongs to the field of medicine application, and particularly discloses application of sarcosine serving as a unique active component to preparation of medicine for preventing and treating obesity and / or hyperlipidemia. The test of treating old mice with sarcosine proves that the sarcosine can reduce the total body mass and fat mass and reduce the body fat rate under the condition that the absolute lean body mass is not influenced. Through tissue staining and biochemical analysis, it is determined that sarcosine can reduce the cross sectional area of visceral adipose tissue (VAT) cells, up-regulate expression of a marker UCP1 of brown adipose tissue in visceral adipose tissue and remarkably reduce the level of triglyceride in plasma. The sarcosine has practical application value in treatment of obesity and hyperlipidemia.

The invention provides a health plan making method, a health plan making device and electronic equipment, which can be applied to the field of electronic equipment. In the technical scheme provided by the invention, the electronic equipment obtains a target weight reduction rate proportion of a user and a current body weight of the user, the target weight reduction rate proportion is a weight reduction rate proportion expected by the user, and the weight reduction rate proportion is a proportion of the body weight reduced in a first unit duration in the current body weight; determining the weight loss fat content corresponding to the target weight loss rate proportion, wherein the weight loss fat content is the proportion of the fat mass in the reduced body weight to the reduced body weight; and based on the weight loss fat content corresponding to the target weight loss rate ratio, the target weight loss rate ratio, the current body weight of the user, the fat calorie per unit weight and the lean body calorie per unit weight, determining a calorie gap of the user in the second unit time length, thereby providing a matched fat loss exercise plan for the user.

The present application relates to use of Ligilactobacillus salivarius in preparing a drug for preventing and / or treating diseases associated with overweight and / or obesity . The strain can inhibit the weight growth of a high-fat diet-induced obesity model mouse, reduce the blood lipid level of the high-fat diet-induced obesity model mouse, improve the liver injury index of the high-fat diet-induced obesity model mouse, reduce the area of white adipose cells of the high-fat diet-induced obesity model mouse, improve the colon GLP-1 level of the high-fat diet-induced obesity model mouse, improve the intestinal flora imbalance of the high-fat diet-induced obesity model mouse, and improve the liver glycolipid metabolism of the high-fat diet-induced obesity model mouse; and reduce the waist circumference, hip circumference, body fat mass, BMI, and weight of overweight and overweight and / or obesity volunteers, and maintain the muscle content, promoting overweight and overweight and / or obesity people to carry out safe, effective, and sustainable weight management.

Increase of energy expenditure as an effective treatment of obesity and related disorders is a target for drug research and development. A 15% increase of energy expenditure is believed to be sufficient to achieve significant weight and fat mass reduction while providing meaningful improvement of metabolic parameters. Disclosed herein is a method for pharmacological inhibition of miR-22-3p, which represents a new therapeutic approach for treating human obesity, diabetes, and hypercholesterolemia.

The invention relates to the technical field of human body measurement, and discloses a body index evaluation device, method and system. The basic concept is that the body fat rate of a user is calculated according to the waistline and gender of the user; combining the body fat rate with the height and the weight to calculate one or more of fat mass, subcutaneous fat weight, visceral fat weight, visceral fat grade, segmental fat weight, skeletal muscle weight, segmental muscle weight, sarcopenia evaluation, moisture weight, mineral weight, protein weight and cell moisture of the user; the calculation method of the body fat rate is as follows: the male body fat rate is equal to 36.4-((110-waistline) * 0.6), and the female body fat rate is equal to 48-((110-waistline) * 0.6); and the value range of the waistline is 60 to 110 cm. According to the method, accurate data are obtained through calculation, the user can make preliminary body screening in multiple aspects with extremely low cost, and the method can be used for the category of obesity and sarcopenia so as to reduce the cost of screening related diseases by the government.

The present invention provides a fat mass simulated structure comprising: a granular material having a push-in strength at 10°C of 2×103 N / m2 or more; and an ionic cross-linked polymer which is cross-linked by ions. The granular material has a volume average grain size of 50 μm to 500 μm; the granular material contains vegetable oil at 30 mass% or more with respect to the entire granular material, the vegetable oil having an unsaturated fatty acid ratio of 50 mass% or more and has a melting point of 0°C or less; and the granular material is in liquid form at 35°C and in solid form at 10°C. The present invention also provides: a method for producing a fat mass simulation structure; and a meat substitute.

The invention provides a health plan making method, a health plan making device and electronic equipment, which can be applied to the field of electronic equipment. In the technical scheme provided by the invention, the electronic equipment obtains a target weight reduction rate proportion of a user and a current body weight of the user, the target weight reduction rate proportion is a weight reduction rate proportion expected by the user, and the weight reduction rate proportion is a proportion of the body weight reduced in a first unit duration in the current body weight; determining the weight loss fat content corresponding to the target weight loss rate proportion, wherein the weight loss fat content is the proportion of the fat mass in the reduced body weight to the reduced body weight; and based on the weight loss fat content corresponding to the target weight loss rate ratio, the target weight loss rate ratio, the current body weight of the user, the fat calorie per unit weight and the lean body calorie per unit weight, determining a calorie gap of the user in the second unit time length, thereby providing a matched fat loss exercise plan for the user.

Administration of certain chromium complexes in combination with a starch provide unexpected benefits regarding increasing amino acid absorption, protein synthesis, exercise tolerance, lean muscle mass, skeletal muscle hypertrophy, muscle power, muscle endurance, muscle strength, FSR, and decreasing delayed onset muscle soreness, muscle protein breakdown, and fat mass.

The present invention relates to a transgenic plant having increased biomass, yield, and / or abiotic stress tolerance. In particular, the present invention relates to a transgenic plant or plant cell into which a nucleic acid molecule encoding an RNA demethylase FTO (fat mass associated with obesity) protein is introduced. The present disclosure also provides methods of producing plants having increased biomass, yield, and / or abiotic stress tolerance.

The present disclosure relates to a method of preventing or treating a disease or disorder in a subject in need thereof, wherein administration of a composition of the present disclosure is effective to result in an increase of energy expenditure in the subject. The present disclosure provides a method of reducing fat mass and / or improving glycemic control in a subject in need thereof. The present disclosure provides a method of promoting weight loss and weight maintenance. The present disclosure provides a method of maintaining lean mass. Compositions for use in the methods include a compound of formula (I), (II), or (III), or pharmaceutically acceptable salts thereof, or in combination with a compound selected from the group consisting of an ACC2 inhibitor and an incretin mimetic.

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.

The present invention is directed towards a transgenic plant that has an increased biomass, yield and / or abiotic stress tolerance. In particular, the present invention is directed to a transgenic plant or plant cell in which a nucleic acid molecule encoding an RNA demethylase FTO (fat mass and obesity-associated) protein is introduced. Also provided by the disclosure are methods of producing the plants with increased biomass, yield and / or abiotic stress tolerance.

Disclosed herein are therapeutic uses of myostatin-selective inhibitors, such as myostatin-selective inhibitors, for treating metabolic disorders, such as obesity. Data presented herein support the notion that selectively targeting myostatin without inhibiting Activin A can achieve equivalent or enhanced efficacy when used in conjunction with a GLP-1 receptor agonist in improving body composition, as compared to broadly antagonizing the ActRII pathway in conjunction with a GLP-1 receptor agonist. Administration of a myostatin-selective inhibitor can prolong the effect of semaglutide on fat mass loss. Moreover, administration of a myostatin-selective inhibitor can elicit positive effects on bone in all parameters evaluated, indicating that diet- or inflammation-induced bone atrophy may be prevented by selective inhibition of the myostatin pathway.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

Provided is a fat mass composition which contains a granular body that contains an oil or fat and an edible ionically-crosslinkable polymer that is crosslinked by a cation, and which is characterized in that: in at least one cross-section that is perpendicular to the longitudinal direction; when the length of the line having the largest length between the two points is defined as b and the length of the line having the largest length among lines perpendicular to the line having the largest length between the two points is defined as a, b / a is 2.00 or more, and a is a.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

1. The name of the design product: liver fat measuring instrument. 2. The use of the design product: for detecting and evaluating liver fat. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

Disclosed is a traditional Chinese medicine composition for preventing and / or treating sarcopenia. The traditional Chinese medicine composition comprises, in parts by weight, 9-11 parts of Citri Reticulatae Pericarpium, 9-11 parts of Achyranthis Bidentatae Radix, 9-11 parts of Hordei Germinatus Fructus, 9-11 parts of Drynariae Rhizoma, 9-11 parts of Eucommiae Cortex, 9-11 parts of Lycii Fructus, 13.5-16.5 parts of Astragali Radix, and 13.5-16.5 parts of Cibotii Rhizoma. The traditional Chinese medicine composition in the present invention can improve the muscle strength, muscle mass and muscle functions, reduce the body fat mass, and delay the aging process, and has no significant influence on the food intake, suggesting that the traditional Chinese medicine composition can be used as a medicine for treating sarcopenia.

Provided herein are methods of reducing body weight and / or fat mass in a subject in need thereof relative to a control. In some embodiments, the present technology comprises a method of treating, preventing, or reducing body weight gain after a weight loss in a subject in need thereof. The methods comprise administering a non-naturally occurring melanocortin analog to the subject.

Systems and methods for treating cellulite, including apparatus applying or methods involving separating a membrane to eliminate or reduce cellulite appearance. In one method, an interventional tool is placed between tissue layers to act and treat septums connecting the tissue layers containing fat deposits therebetween.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

Provided are a fat mass-simulating structure, a method for producing the same, and a meat substitute, comprising: granules that contain oil / fat, are solid at 10°C and liquid at 35°C; an edible ion-crosslinkable polymer crosslinked with cations; and a polyvalent metal salt having a solubility in water at 20°C of 1 g / 100 g or less. The volume average particle diameter of the granules is 50-500 μm.

The invention relates to the technical field of health assessment, in particular to an intelligent assessment method based on the nutrition state of leukemia children in the chemotherapy period. The method comprises the steps of obtaining the daily weight, muscle mass, fat mass and nutrition intake of a child patient in a chemotherapy period, determining an absorption capacity coefficient based on the change of the nutrition intake and the weight, determining a reserve capacity coefficient for converting nutrition intake into effective reserve in the period based on the change of the muscle mass and the change of the fat mass in adjacent days in the period, and determining a nutrition state index by combining the absorption capacity coefficient and the reserve capacity coefficient, determining a nutrition evaluation coefficient according to the nutrition state indexes of all the time periods of the chemotherapy period before the current moment, and performing risk analysis based on the nutrition evaluation coefficient. The method can more comprehensively and reliably evaluate the nutrition state of the child patient in the chemotherapy period, and improves the accuracy of nutrition state evaluation.

Body fat measuring device which features: several electrodes (HR, HL, BU1 - BU4, BL1 - BL4, FR, FL, FR', FL') to establish contact with predetermined areas of the surface of the body of a test subject; a body impedance measurement unit (12) which measures a body impedance of the body of the test subject using the multiple electrodes (HR, HL, BU1 - BU4, BL1 - BL4, FR, FL, FR', FL'); a torso width measurement unit (13) for measuring the torso width and torso depth of the test subject; and a body fat mass calculation unit (14) which calculates a body fat mass based on the body impedance measured by the body impedance measurement unit (12) and the trunk width and trunk depth measured by the trunk width measurement unit (13), wherein the multiple electrodes include at least dorsal surface electrodes (BU1 - BU4, BL1 - BL4) for establishing contact with the surface of a dorsal area corresponding to a surface on the dorsal side of the trunk area of ​​the test subject; wherein the body fat measuring device further comprises a frame-shaped mounting unit (100A) capable of being arranged in such a way that, during an attached state, it surrounds the trunk area of ​​the test subject in order to bring the back surface electrodes (BU1 - BU4, BL1 - BL4) into contact with the back surface of the test subject in a pressurized state; wherein the back surface electrodes (BU1 - BU4, BL1 - BL4) are provided in an exposed state on a surface of the mounting unit (100A - 100G); wherein the fuselage width detection unit (24A) is provided in the mounting unit (100A - 100G); wherein the multiple electrodes further comprise upper limb electrodes (HR, HL) to establish contact with the surfaces of the upper limbs of the test subject; and wherein the upper limb electrodes (HR, HL) are provided in an exposed state on the surface of the application unit (100A - 100G).

A bacterium belonging to a novel bacterial genus, Dysosmobacter. Also, the therapeutic, nutraceutical and cosmetic use thereof. The uses include methods for treating a disorder, promoting weight loss, decreasing food intake, increasing muscle mass, decreasing fat mass, increasing satiety, and / or decreasing weight gain associated with food intake in a subject, including administering to the subject at least one isolated bacterium belonging to the genus Dysosmobacter and / or a variant thereof and / or fragments thereof.

The present technology comprises methods of treating, preventing, reducing, or otherwise ameliorating one or more symptoms or conditions that may benefit from weight gain or a reduction in weight loss. The methods comprise administering a non-naturally occurring melanocortin analog of the present technology to a subject in need thereof. The methods may promote fat gain (e.g., epididymal fat or perirenal fat), increase muscle mass, increase body weight, accelerate weight gain, increase fat mass to lean mass ratio, improve body composition and / or BMI (e.g., for underweight conditions), increase waist circumference, increase cardiac mass, increase brain mass, or any combination thereof, relative to a control.

To provide capability for auditing whether medical cosmetic treatment is being appropriately provided or not.SOLUTION: Disclosed herein is a medical audit system for generating models regarding procedures from a captured video image of treatment and analyzing the newly acquired video image to audit whether or not the treatment in the video image is being executed according to the procedures. The treatment involves collecting fat by the syringe method using a syringe, where the amount of naturally separated fat is approximately 30-80 cc. The present invention can efficiently audit whether each procedure of the treatment is being accurately carried out or not. Such an arrangement can improve treatment quality and ensure patient safety. The system can also reduce human errors and save time and resources.SELECTED DRAWING: None

Provided are methods of increasing body weight of and / or increasing food consumption in a metabolically unchallenged subject using non-naturally occurring melanocortin analogs. Also provided are methods of stimulating appetite in a subject via administration of non-naturally occurring melanocortin analogs. The non-naturally occurring melanocortin analog can be present in a pharmaceutical composition and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass of the subject.